The Experts below are selected from a list of 3096 Experts worldwide ranked by ideXlab platform
Rudolf Valenta - One of the best experts on this subject based on the ideXlab platform.
-
Microarrayed Recombinant Allergens for diagnosis of allergy.
Clinical & Experimental Allergy, 2020Co-Authors: Christian Harwanegg, Sylvia Laffer, Dietrich Kraft, Susanne Spitzauer, R. Hiller, Manfred W. Mueller, Rudolf ValentaAbstract:Summary We suggest that the coapplication of Recombinant Allergens and microarray technology can lead to the development of new forms of multi-Allergen tests which allow the determining and monitoring of complex sensitization profiles of allergic patients in single assays. The Allergen extracts which have so far been used for diagnosis only allowed the determining of whether an allergic patient is sensitized against a particular Allergen source, but the disease-eliciting Allergens could not be identified. Through the application of Recombinant DNA technology a rapidly growing panel of Recombinant Allergen molecules has become available which meanwhile comprises the epitope spectrum of most of the important Allergen sources. We demonstrate that microarray technology can be used to establish multi-Allergen tests consisting of microarrayed Recombinant Allergen molecules. Microarrayed Recombinant Allergens can be used to determine and monitor the profile of disease-eliciting Allergens using single tests that require minute amounts of serum from allergic patients. The wealth of diagnostic information gained through microarray-based allergy testing will likely improve diagnosis, prevention and treatment of allergy.
-
Recombinant Allergens for immunotherapy: state of the art.
Current Opinion in Allergy and Clinical Immunology, 2019Co-Authors: Yury Zhernov, Mirela Curin, Musa Khaitov, Alexander Karaulov, Rudolf ValentaAbstract:Purpose of review More than 30 years ago, the first molecular structures of Allergens were elucidated and defined Recombinant Allergens became available. We review the state of the art regarding molecular AIT with the goal to understand why progress in this field has been slow, although there is huge potential for treatment and Allergen-specific prevention. Recent findings On the basis of Allergen structures, several AIT strategies have been developed and were advanced into clinical evaluation. In clinical AIT trials, promising results were obtained with Recombinant and synthetic Allergen derivatives inducing Allergen-specific IgG antibodies, which interfered with Allergen recognition by IgE whereas clinical efficacy could not yet be demonstrated for approaches targeting only Allergen-specific T-cell responses. Available data suggest that molecular AIT strategies have many advantages over Allergen extract-based AIT. Summary Clinical studies indicate that Recombinant Allergen-based AIT vaccines, which are superior to existing Allergen extract-based AIT can be developed for respiratory, food and venom allergy. Allergen-specific preventive strategies based on Recombinant Allergen-based vaccine approaches and induction of T-cell tolerance are on the horizon and hold promise that allergy can be prevented. However, progress is limited by lack of resources needed for clinical studies, which are necessary for the development of these innovative strategies.
-
Recombinant Allergen and peptide based approaches for allergy prevention by oral tolerance
Seminars in Immunology, 2017Co-Authors: Raffaela Campana, Birgit Linhart, Hueyjy Huang, Raphaela Freidl, Susanne Vrtala, Thomas Wekerle, A V Karaulov, Rudolf ValentaAbstract:Abstract Several studies conducted in animal models for immunologically-mediated hypersensitivity diseases have shown that oral administration of antigens early in life can prevent the development of specific humoral and cellular immune responses and thus hypersensitivity reactions to the respective antigens. Such data were also obtained in models for Immunoglobulin E (IgE)-associated allergy, the most common hypersensitivity disease affecting more than 25% of the population. Based on data obtained in animal models for allergy several clinical intervention studies have been conducted in children to study if oral administration of materials containing Allergens or Allergen-derived peptides early in life can prevent the subsequent development of allergy. In this article we argue that oral tolerance induction could be a potent way to prevent allergy and may be even improved regarding efficacy provided that well-defined Allergen molecules and/or Allergen-derivatives were used in optimized dose regimens and periods of intervention. The knowledge regarding the molecular and immunological characteristics of Allergens which has been achieved in the last decades is a prerequisite for such a treatment. In fact, defined Recombinant Allergens/Allergen derivatives and Allergen-derived synthetic peptides from the most common Allergen sources are now available for targeted intervention. Moreover, molecular allergy diagnosis allows deciphering the disease-causing relevant Allergens for different regions in the world allowing composing cocktails of tolerogens according to the needs of populations from different parts of the world. Furthermore, it is suggested to use defined Allergen molecules and epitopes in the analysis of clinical tolerance studies. This will allow understanding if clinical unresponsiveness is due to true immunological tolerance or to other mechanisms such as induction of blocking antibodies or cellular immunomodulation. Using molecularly defined tolerogens it can now be explored if oral tolerance induction is a powerful strategy to prevent IgE-associated allergy.
-
vaccine development for Allergen specific immunotherapy based on Recombinant Allergens and synthetic Allergen peptides lessons from the past and novel mechanisms of action for the future
The Journal of Allergy and Clinical Immunology, 2016Co-Authors: Rudolf Valenta, Raffaela Campana, M Focketejkl, Verena NiederbergerAbstract:In the past, the development of more effective, safe, convenient, broadly applicable, and easy to manufacture vaccines for Allergen-specific immunotherapy (AIT) has been limited by the poor quality of natural Allergen extracts. Progress made in the field of molecular Allergen characterization has now made it possible to produce defined vaccines for AIT and eventually for preventive allergy vaccination based on Recombinant DNA technology and synthetic peptide chemistry. Here we review the characteristics of Recombinant and synthetic allergy vaccines that have reached clinical evaluation and discuss how molecular vaccine approaches can make AIT more safe and effective and thus more convenient. Furthermore, we discuss how new technologies can facilitate the reproducible manufacturing of vaccines of pharmaceutical grade for inhalant, food, and venom Allergens. Allergy vaccines in clinical trials based on Recombinant Allergens, Recombinant Allergen derivatives, and synthetic peptides allow us to target selectively different immune mechanisms, and certain of those show features that might make them applicable not only for therapeutic but also for prophylactic vaccination.
-
real life study for the diagnosis of house dust mite allergy the value of Recombinant Allergen based ige serology
International Archives of Allergy and Immunology, 2016Co-Authors: Sven Becker, Rudolf Valenta, Susanne Vrtala, Matthias F. Kramer, Thomas Schlederer, Mareike Haack, Yvonne Resch, Christian Lupinek, Moritz GrögerAbstract:Background: Dermatophagoides pteronyssinus is one of the most important perennial Allergen sources worldwide. Molecular diagnostics using the co
Luc S De Clerck - One of the best experts on this subject based on the ideXlab platform.
-
component resolved diagnosis of wasp yellow jacket venom allergy
Clinical & Experimental Allergy, 2013Co-Authors: Margaretha A Faber, Josee E Leysen, Valentina Sabato, Chris H Bridts, Luc S De ClerckAbstract:SummaryBackground Wasp venom allergy is a potentially life-threatening condition with serious consequences of diagnostic error. Objective To assess whether component-resolved diagnosis, using non-glycosylated Recombinant Allergen components from yellow jacket can add to the diagnosis of wasp venom allergy. Methods In total, 148 patients with a wasp (yellow jacket) allergy were included, 91 with unequivocal tests, 26 with double positivity of serum-specific IgE (sIgE) to both venoms, 21 with discrepant sIgE and skin test results and finally 10 having their diagnosis only confirmed by basophil activation test (negative sIgE and skin test results). Specific IgE to Recombinant species-specific Allergen components Ves v 1 and Ves v 5 from yellow jacket, Api m 1 from honeybee and Ves v 5 complemented wasp venom were tested by ImmunoCAP. Results Overall, combined use of sIgE to rVes v 1 and rVes v 5 allowed correct diagnosis in 139 of the 148 patients (94%) and rApi m 1 was demonstrable in only one patient. Supplementing the traditional yellow jacket allergosorbent with rVes v 5 allowed to correctly diagnose wasp allergy in patients sensitized to Ves v 5 but demonstrating a negative sIgE to wasp venom. Conclusion Component-resolved diagnoses with the wasp-specific Recombinant Allergen components Ves v 1 and Ves v 5 is a reliable method to diagnose yellow jacket allergy and can help to take out the sting of difficult cases. However, as the number of patients with doubt after conventional tests is small, larger collaborative studies are needed to draw more definitive conclusions. Whether the rVes v 5 supplemented yellow jacket allergosorbent constitutes an asset in the diagnostic management of wasp venom allergy remains to be further established.
-
Component-resolved diagnosis of wasp (yellow jacket) venom allergy
Clinical and Experimental Allergy, 2013Co-Authors: Didier G. Ebo, Milosz Faber, Josee E Leysen, Valentina Sabato, Chris H Bridts, Luc S De ClerckAbstract:BACKGROUND: Wasp venom allergy is a potentially life-threatening condition with serious consequences of diagnostic error.\n\nOBJECTIVE: To assess whether component-resolved diagnosis, using non-glycosylated Recombinant Allergen components from yellow jacket can add to the diagnosis of wasp venom allergy.\n\nMETHODS: In total, 148 patients with a wasp (yellow jacket) allergy were included, 91 with unequivocal tests, 26 with double positivity of serum-specific IgE (sIgE) to both venoms, 21 with discrepant sIgE and skin test results and finally 10 having their diagnosis only confirmed by basophil activation test (negative sIgE and skin test results). Specific IgE to Recombinant species-specific Allergen components Ves v 1 and Ves v 5 from yellow jacket, Api m 1 from honeybee and Ves v 5 complemented wasp venom were tested by ImmunoCAP.\n\nRESULTS: Overall, combined use of sIgE to rVes v 1 and rVes v 5 allowed correct diagnosis in 139 of the 148 patients (94%) and rApi m 1 was demonstrable in only one patient. Supplementing the traditional yellow jacket allergosorbent with rVes v 5 allowed to correctly diagnose wasp allergy in patients sensitized to Ves v 5 but demonstrating a negative sIgE to wasp venom.\n\nCONCLUSION: Component-resolved diagnoses with the wasp-specific Recombinant Allergen components Ves v 1 and Ves v 5 is a reliable method to diagnose yellow jacket allergy and can help to take out the sting of difficult cases. However, as the number of patients with doubt after conventional tests is small, larger collaborative studies are needed to draw more definitive conclusions. Whether the rVes v 5 supplemented yellow jacket allergosorbent constitutes an asset in the diagnostic management of wasp venom allergy remains to be further established.
Verena Niederberger - One of the best experts on this subject based on the ideXlab platform.
-
vaccine development for Allergen specific immunotherapy based on Recombinant Allergens and synthetic Allergen peptides lessons from the past and novel mechanisms of action for the future
The Journal of Allergy and Clinical Immunology, 2016Co-Authors: Rudolf Valenta, Raffaela Campana, M Focketejkl, Verena NiederbergerAbstract:In the past, the development of more effective, safe, convenient, broadly applicable, and easy to manufacture vaccines for Allergen-specific immunotherapy (AIT) has been limited by the poor quality of natural Allergen extracts. Progress made in the field of molecular Allergen characterization has now made it possible to produce defined vaccines for AIT and eventually for preventive allergy vaccination based on Recombinant DNA technology and synthetic peptide chemistry. Here we review the characteristics of Recombinant and synthetic allergy vaccines that have reached clinical evaluation and discuss how molecular vaccine approaches can make AIT more safe and effective and thus more convenient. Furthermore, we discuss how new technologies can facilitate the reproducible manufacturing of vaccines of pharmaceutical grade for inhalant, food, and venom Allergens. Allergy vaccines in clinical trials based on Recombinant Allergens, Recombinant Allergen derivatives, and synthetic peptides allow us to target selectively different immune mechanisms, and certain of those show features that might make them applicable not only for therapeutic but also for prophylactic vaccination.
-
Recombinant Allergen based provocation testing
Methods, 2014Co-Authors: Verena Niederberger, Julia Eckldorna, G PauliAbstract:Over the last 25 years, Recombinant Allergens from all important Allergen sources have been cloned and are now available as Recombinant proteins. These molecules can be produced in practically unlimited amounts without biological or batch-to-batch variability. It has been shown in provocation tests that Recombinant Allergens have similar clinical effects as their natural counterparts. With the help of these tools it is possible to reveal the precise reactivity profiles of patients and to uncover and differentiate cross-reactivity from genuine sensitization to an Allergen source. Although it has been shown some time ago that it would be possible to replace crude Allergen extracts with Recombinant Allergens for skin prick testing, and even though the use of Allergen components can improve routine diagnosis, these tools are still not available for clinical routine applications. The use of provocation tests is a crucial step in the development of new, hypoAllergenic vaccines for therapy of allergic disease. Here we describe important provocation methods (skin prick test, intradermal test, atopy patch test, nasal provocation, colonoscopic provocation test) and give an overview of the clinical provocation studies which have been performed with Recombinant Allergens so far.
-
Recombinant Allergens: What does the future hold?
The Journal of Allergy and Clinical Immunology, 2011Co-Authors: Rudolf Valenta, Margit Focke-tejkl, Katharina Marth, Katarzyna Niespodziana, Angela Neubauer, Hans Huber, Verena NiederbergerAbstract:This year we are celebrating not only the centenary of Allergen-specific immunotherapy but also the 10-year anniversary of the first administration of Recombinant Allergen–based vaccines to allergic patients. By using Recombinant DNA technology, defined and safe allergy vaccines can be produced that allow us to overcome many, if not all, of the problems associated with the use of natural Allergen extracts, such as insufficient quality, Allergenic activity, and poor immunogenicity. Here we provide an update of clinical studies with Recombinant Allergen–based vaccines, showing that some of these vaccines have undergone successful clinical evaluation up to phase III studies. Furthermore, we introduce a strategy for Allergen-specific immunotherapy based on Recombinant fusion proteins consisting of viral carrier proteins and Allergen-derived peptides without Allergenic activity, which holds the promise of being free of side effects and eventually being useful for prophylactic vaccination.
-
Recombinant Allergens for Allergen-specific immunotherapy: 10 years anniversary of immunotherapy with Recombinant Allergens
Allergy: European Journal of Allergy and Clinical Immunology, 2011Co-Authors: Rudolf Valenta, Ines Swoboda, Birgit Linhart, Verena NiederbergerAbstract:The broad applicability of Allergen-specific immunotherapy for the treatment and eventually prevention of IgE-mediated allergy is limited by the poor quality and Allergenic activity of natural Allergen extracts that are used for the production of current allergy vaccines. Today, the genetic code of the most important Allergens has been deciphered; Recombinant Allergens equalling their natural counterparts have been produced for diagnosis and immunotherapy, and a large panel of genetically modified Allergens with reduced Allergenic activity has been characterized to improve safety of immunotherapy and explore Allergen-specific prevention strategies. Successful immunotherapy studies have been performed with Recombinant Allergens and hypoAllergenic Allergen derivatives and will lead to the registration of the first Recombinant Allergen-based vaccines in the near future. There is no doubt that Recombinant Allergen-based vaccination strategies will be generally applicable to most Allergen sources, including respiratory, food and venom Allergens and allow to produce safe allergy vaccines for the treatment of the most common forms of IgE-mediated allergies.
-
Recombinant Allergens: What does the future hold?
Journal of Allergy and Clinical Immunology, 2011Co-Authors: Rudolf Valenta, Margit Focke-tejkl, Katharina Marth, Katarzyna Niespodziana, Angela Neubauer, Hans Huber, Verena NiederbergerAbstract:This year we are celebrating not only the centenary of Allergen-specific immunotherapy but also the 10-year anniversary of the first administration of Recombinant Allergen-based vaccines to allergic patients. By using Recombinant DNA technology, defined and safe allergy vaccines can be produced that allow us to overcome many, if not all, of the problems associated with the use of natural Allergen extracts, such as insufficient quality, Allergenic activity, and poor immunogenicity. Here we provide an update of clinical studies with Recombinant Allergen-based vaccines, showing that some of these vaccines have undergone successful clinical evaluation up to phase III studies. Furthermore, we introduce a strategy for Allergen-specific immunotherapy based on Recombinant fusion proteins consisting of viral carrier proteins and Allergen-derived peptides without Allergenic activity, which holds the promise of being free of side effects and eventually being useful for prophylactic vaccination. © 2010 American Academy of Allergy, Asthma & Immunology.
Josee E Leysen - One of the best experts on this subject based on the ideXlab platform.
-
component resolved diagnosis of wasp yellow jacket venom allergy
Clinical & Experimental Allergy, 2013Co-Authors: Margaretha A Faber, Josee E Leysen, Valentina Sabato, Chris H Bridts, Luc S De ClerckAbstract:SummaryBackground Wasp venom allergy is a potentially life-threatening condition with serious consequences of diagnostic error. Objective To assess whether component-resolved diagnosis, using non-glycosylated Recombinant Allergen components from yellow jacket can add to the diagnosis of wasp venom allergy. Methods In total, 148 patients with a wasp (yellow jacket) allergy were included, 91 with unequivocal tests, 26 with double positivity of serum-specific IgE (sIgE) to both venoms, 21 with discrepant sIgE and skin test results and finally 10 having their diagnosis only confirmed by basophil activation test (negative sIgE and skin test results). Specific IgE to Recombinant species-specific Allergen components Ves v 1 and Ves v 5 from yellow jacket, Api m 1 from honeybee and Ves v 5 complemented wasp venom were tested by ImmunoCAP. Results Overall, combined use of sIgE to rVes v 1 and rVes v 5 allowed correct diagnosis in 139 of the 148 patients (94%) and rApi m 1 was demonstrable in only one patient. Supplementing the traditional yellow jacket allergosorbent with rVes v 5 allowed to correctly diagnose wasp allergy in patients sensitized to Ves v 5 but demonstrating a negative sIgE to wasp venom. Conclusion Component-resolved diagnoses with the wasp-specific Recombinant Allergen components Ves v 1 and Ves v 5 is a reliable method to diagnose yellow jacket allergy and can help to take out the sting of difficult cases. However, as the number of patients with doubt after conventional tests is small, larger collaborative studies are needed to draw more definitive conclusions. Whether the rVes v 5 supplemented yellow jacket allergosorbent constitutes an asset in the diagnostic management of wasp venom allergy remains to be further established.
-
Component-resolved diagnosis of wasp (yellow jacket) venom allergy
Clinical and Experimental Allergy, 2013Co-Authors: Didier G. Ebo, Milosz Faber, Josee E Leysen, Valentina Sabato, Chris H Bridts, Luc S De ClerckAbstract:BACKGROUND: Wasp venom allergy is a potentially life-threatening condition with serious consequences of diagnostic error.\n\nOBJECTIVE: To assess whether component-resolved diagnosis, using non-glycosylated Recombinant Allergen components from yellow jacket can add to the diagnosis of wasp venom allergy.\n\nMETHODS: In total, 148 patients with a wasp (yellow jacket) allergy were included, 91 with unequivocal tests, 26 with double positivity of serum-specific IgE (sIgE) to both venoms, 21 with discrepant sIgE and skin test results and finally 10 having their diagnosis only confirmed by basophil activation test (negative sIgE and skin test results). Specific IgE to Recombinant species-specific Allergen components Ves v 1 and Ves v 5 from yellow jacket, Api m 1 from honeybee and Ves v 5 complemented wasp venom were tested by ImmunoCAP.\n\nRESULTS: Overall, combined use of sIgE to rVes v 1 and rVes v 5 allowed correct diagnosis in 139 of the 148 patients (94%) and rApi m 1 was demonstrable in only one patient. Supplementing the traditional yellow jacket allergosorbent with rVes v 5 allowed to correctly diagnose wasp allergy in patients sensitized to Ves v 5 but demonstrating a negative sIgE to wasp venom.\n\nCONCLUSION: Component-resolved diagnoses with the wasp-specific Recombinant Allergen components Ves v 1 and Ves v 5 is a reliable method to diagnose yellow jacket allergy and can help to take out the sting of difficult cases. However, as the number of patients with doubt after conventional tests is small, larger collaborative studies are needed to draw more definitive conclusions. Whether the rVes v 5 supplemented yellow jacket allergosorbent constitutes an asset in the diagnostic management of wasp venom allergy remains to be further established.
Valentina Sabato - One of the best experts on this subject based on the ideXlab platform.
-
component resolved diagnosis of wasp yellow jacket venom allergy
Clinical & Experimental Allergy, 2013Co-Authors: Margaretha A Faber, Josee E Leysen, Valentina Sabato, Chris H Bridts, Luc S De ClerckAbstract:SummaryBackground Wasp venom allergy is a potentially life-threatening condition with serious consequences of diagnostic error. Objective To assess whether component-resolved diagnosis, using non-glycosylated Recombinant Allergen components from yellow jacket can add to the diagnosis of wasp venom allergy. Methods In total, 148 patients with a wasp (yellow jacket) allergy were included, 91 with unequivocal tests, 26 with double positivity of serum-specific IgE (sIgE) to both venoms, 21 with discrepant sIgE and skin test results and finally 10 having their diagnosis only confirmed by basophil activation test (negative sIgE and skin test results). Specific IgE to Recombinant species-specific Allergen components Ves v 1 and Ves v 5 from yellow jacket, Api m 1 from honeybee and Ves v 5 complemented wasp venom were tested by ImmunoCAP. Results Overall, combined use of sIgE to rVes v 1 and rVes v 5 allowed correct diagnosis in 139 of the 148 patients (94%) and rApi m 1 was demonstrable in only one patient. Supplementing the traditional yellow jacket allergosorbent with rVes v 5 allowed to correctly diagnose wasp allergy in patients sensitized to Ves v 5 but demonstrating a negative sIgE to wasp venom. Conclusion Component-resolved diagnoses with the wasp-specific Recombinant Allergen components Ves v 1 and Ves v 5 is a reliable method to diagnose yellow jacket allergy and can help to take out the sting of difficult cases. However, as the number of patients with doubt after conventional tests is small, larger collaborative studies are needed to draw more definitive conclusions. Whether the rVes v 5 supplemented yellow jacket allergosorbent constitutes an asset in the diagnostic management of wasp venom allergy remains to be further established.
-
Component-resolved diagnosis of wasp (yellow jacket) venom allergy
Clinical and Experimental Allergy, 2013Co-Authors: Didier G. Ebo, Milosz Faber, Josee E Leysen, Valentina Sabato, Chris H Bridts, Luc S De ClerckAbstract:BACKGROUND: Wasp venom allergy is a potentially life-threatening condition with serious consequences of diagnostic error.\n\nOBJECTIVE: To assess whether component-resolved diagnosis, using non-glycosylated Recombinant Allergen components from yellow jacket can add to the diagnosis of wasp venom allergy.\n\nMETHODS: In total, 148 patients with a wasp (yellow jacket) allergy were included, 91 with unequivocal tests, 26 with double positivity of serum-specific IgE (sIgE) to both venoms, 21 with discrepant sIgE and skin test results and finally 10 having their diagnosis only confirmed by basophil activation test (negative sIgE and skin test results). Specific IgE to Recombinant species-specific Allergen components Ves v 1 and Ves v 5 from yellow jacket, Api m 1 from honeybee and Ves v 5 complemented wasp venom were tested by ImmunoCAP.\n\nRESULTS: Overall, combined use of sIgE to rVes v 1 and rVes v 5 allowed correct diagnosis in 139 of the 148 patients (94%) and rApi m 1 was demonstrable in only one patient. Supplementing the traditional yellow jacket allergosorbent with rVes v 5 allowed to correctly diagnose wasp allergy in patients sensitized to Ves v 5 but demonstrating a negative sIgE to wasp venom.\n\nCONCLUSION: Component-resolved diagnoses with the wasp-specific Recombinant Allergen components Ves v 1 and Ves v 5 is a reliable method to diagnose yellow jacket allergy and can help to take out the sting of difficult cases. However, as the number of patients with doubt after conventional tests is small, larger collaborative studies are needed to draw more definitive conclusions. Whether the rVes v 5 supplemented yellow jacket allergosorbent constitutes an asset in the diagnostic management of wasp venom allergy remains to be further established.